CN113811360A - 用于hiv治疗的化合物 - Google Patents

用于hiv治疗的化合物 Download PDF

Info

Publication number
CN113811360A
CN113811360A CN202080030422.7A CN202080030422A CN113811360A CN 113811360 A CN113811360 A CN 113811360A CN 202080030422 A CN202080030422 A CN 202080030422A CN 113811360 A CN113811360 A CN 113811360A
Authority
CN
China
Prior art keywords
fluoro
purin
ethynyl
amino
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080030422.7A
Other languages
English (en)
Chinese (zh)
Inventor
M.A.德拉罗萨
J.F.米勒
D.特梅尔科夫
E.J.韦尔图伊森
B.N.奈杜
V.萨马诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
ViiV Healthcare Co
Original Assignee
GlaxoSmithKline LLC
ViiV Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69845479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN113811360(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline LLC, ViiV Healthcare Co filed Critical GlaxoSmithKline LLC
Publication of CN113811360A publication Critical patent/CN113811360A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202080030422.7A 2019-03-06 2020-03-04 用于hiv治疗的化合物 Pending CN113811360A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814316P 2019-03-06 2019-03-06
US62/814,316 2019-03-06
PCT/IB2020/051878 WO2020178767A1 (en) 2019-03-06 2020-03-04 Compounds useful in hiv therapy

Publications (1)

Publication Number Publication Date
CN113811360A true CN113811360A (zh) 2021-12-17

Family

ID=69845479

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080030422.7A Pending CN113811360A (zh) 2019-03-06 2020-03-04 用于hiv治疗的化合物

Country Status (22)

Country Link
US (4) US12240853B2 (https=)
EP (1) EP3934760A1 (https=)
JP (1) JP2022525013A (https=)
KR (1) KR20210136052A (https=)
CN (1) CN113811360A (https=)
AR (1) AR118240A1 (https=)
AU (1) AU2020231934B2 (https=)
BR (1) BR112021017604A2 (https=)
CA (1) CA3132112A1 (https=)
CL (1) CL2021002309A1 (https=)
CO (1) CO2021012579A2 (https=)
CR (1) CR20210460A (https=)
EA (1) EA202192433A1 (https=)
IL (1) IL285894A (https=)
MA (1) MA55200A (https=)
MX (1) MX2021010700A (https=)
PE (1) PE20212089A1 (https=)
PH (1) PH12021500034A1 (https=)
SG (1) SG11202109253SA (https=)
TW (1) TW202102233A (https=)
WO (1) WO2020178767A1 (https=)
ZA (1) ZA202106096B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3146679A1 (en) * 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
KR20220066303A (ko) 2019-09-11 2022-05-24 더 스크립스 리서치 인스티튜트 항바이러스 전구약물 및 이의 약제학적 조성물
JP7703538B2 (ja) * 2019-12-09 2025-07-07 ヴィーブ、ヘルスケア、カンパニー カボテグラビルを含んでなる医薬組成物
WO2021188959A1 (en) * 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
KR102918401B1 (ko) * 2020-12-30 2026-01-26 서던 유니버시티 오브 사이언스 앤드 테크놀로지 코로나 바이러스 감염을 치료하기 위한 방법 및 변형된 뉴클레오사이드
EP4281081A4 (en) * 2021-01-25 2025-05-14 Brii Biosciences, Inc. ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF
EP4281083A4 (en) * 2021-01-25 2025-01-01 Brii Biosciences, Inc. COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS
WO2022182604A1 (en) * 2021-02-23 2022-09-01 Viiv Healthcare Company Compounds useful in hiv treatment
CR20250310A (es) * 2023-01-30 2025-08-25 Merck Sharp & Dohme Llc Profármacos de inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4'
AU2024353051A1 (en) 2023-09-27 2026-03-12 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions
AU2023466962A1 (en) 2023-09-27 2026-03-12 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1589026A1 (en) * 2004-03-24 2005-10-26 Yamasa Corporation 4'-C-Substituted-2-Haloadenosine derivative
CN108289931A (zh) * 2015-09-23 2018-07-17 默沙东公司 4’-取代的核苷逆转录酶抑制剂及其制备

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ATE250622T1 (de) 1999-05-12 2003-10-15 Yamasa Corp 4'-c-ethynyl-pyrimidine nukleoside
EP1378509A4 (en) 2001-03-19 2009-03-25 Ono Pharmaceutical Co DRUGS WITH TRIAZASPIRO ç5.5] UNDECANDERIVATES AS ACTIVE SUBSTANCE
US7037718B2 (en) 2001-10-26 2006-05-02 Cornell Research Foundation, Inc. Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
EP2619215B1 (en) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
AR088262A1 (es) 2011-10-06 2014-05-21 Dow Agrosciences Llc Moleculas de acido nucleico que se dirigen a rpa70 y confieren resistencia a plagas de coleopteros
SG10201913554YA (en) 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
GEP201706721B (en) 2012-03-21 2017-08-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AU2014302711A1 (en) 2013-06-26 2015-12-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015054465A1 (en) 2013-10-11 2015-04-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
MA40031A (fr) 2014-06-24 2015-12-30 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
HUE051986T2 (hu) 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
WO2016057866A1 (en) 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
CA2965719A1 (en) * 2014-10-31 2016-05-06 Sandoz Ag Improved fluorination process
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
US11117904B2 (en) 2016-06-23 2021-09-14 Viiv Healthcare Company Compositions and methods for the delivery of therapeutics
US11021510B2 (en) 2016-11-03 2021-06-01 Laurence I. Wu Prodrugs of clofarabine
US20190185508A1 (en) 2017-12-15 2019-06-20 Merck Sharp & Dohme Corp. Deuterated nucleoside reverse transcriptase inhibitors
EP3762396A1 (en) * 2018-03-07 2021-01-13 GlaxoSmithKline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
SG11202009906TA (en) 2018-04-09 2020-11-27 Eisai R&D Man Co Ltd Pladienolide compounds and their use
AU2019317810A1 (en) 2018-08-09 2021-02-25 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in HIV therapy
JP2021536444A (ja) 2018-08-30 2021-12-27 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Ｈｉｖ療法に有用な化合物
US12018435B2 (en) 2019-03-06 2024-06-25 Chemstone, Inc. Liquid dispersions for acyl halides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1589026A1 (en) * 2004-03-24 2005-10-26 Yamasa Corporation 4'-C-Substituted-2-Haloadenosine derivative
CN108289931A (zh) * 2015-09-23 2018-07-17 默沙东公司 4’-取代的核苷逆转录酶抑制剂及其制备

Also Published As

Publication number Publication date
AU2020231934B2 (en) 2023-04-20
TW202102233A (zh) 2021-01-16
US20220411425A1 (en) 2022-12-29
PE20212089A1 (es) 2021-11-04
EA202192433A1 (ru) 2021-12-28
JP2022525013A (ja) 2022-05-11
EP3934760A1 (en) 2022-01-12
US20230174534A1 (en) 2023-06-08
US20260035371A1 (en) 2026-02-05
CA3132112A1 (en) 2020-09-10
CL2021002309A1 (es) 2022-09-20
SG11202109253SA (en) 2021-09-29
MX2021010700A (es) 2021-10-01
MA55200A (fr) 2022-01-12
IL285894A (en) 2021-10-31
BR112021017604A2 (pt) 2021-11-16
WO2020178767A1 (en) 2020-09-10
CR20210460A (es) 2022-02-03
AU2020231934A1 (en) 2021-09-23
US20240182473A1 (en) 2024-06-06
KR20210136052A (ko) 2021-11-16
AU2020231934A8 (en) 2022-03-24
AR118240A1 (es) 2021-09-22
PH12021500034A1 (en) 2022-06-06
US12240853B2 (en) 2025-03-04
ZA202106096B (en) 2023-03-29
CO2021012579A2 (es) 2021-10-20

Similar Documents

Publication Publication Date Title
CN113811360A (zh) 用于hiv治疗的化合物
US11274102B2 (en) Compounds useful in HIV therapy
JP6091520B2 (ja) ベツリンのプロペン酸誘導体
TW201730202A (zh) 樺腦（ｂｅｔｕｌｉｎ）衍生物
RS51226B (sr) Derivati azapeptida kao inhibitori hiv proteaze
JP2021515771A (ja) Ｈｉｖ療法に有用な化合物
JP2021534112A (ja) Ｈｉｖ療法に有用な化合物
JP2021536444A (ja) Ｈｉｖ療法に有用な化合物
US10583140B2 (en) Ingenol analogs, pharmaceutical compositions and methods of use thereof
JP2018528231A (ja) Ｈｉｖ成熟阻害活性を有する化合物
JP2018521093A (ja) Ｈｉｖ感染を予防または治療するためのベツイン誘導体
JP2022543319A (ja) Ｈｉｖ治療に有用な化合物
JP2018521107A (ja) Ｈｉｖ感染を予防または治療するためのベツイン誘導体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211217